{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:03:37Z","timestamp":1772827417229,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejmech.2021.114065","type":"journal-article","created":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T01:39:12Z","timestamp":1640396352000},"page":"114065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Discovery of 2H-chromone-4-one based sulfonamide derivatives as potent retinoic acid receptor-related orphan receptor \u03b3t inverse agonists"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4952-5150","authenticated-orcid":false,"given":"Lei","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Zhi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-yang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Gu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israa","family":"Assani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu-Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Feng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen-Min","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ri-Zhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6569-366X","authenticated-orcid":false,"given":"Zhi-Xin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.114065_bib1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2021.114065_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23\u2212IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2021.114065_bib3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A\u00a0distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2021.114065_bib4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.114065_bib5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.114065_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13555-016-0102-0","article-title":"Ixekizumab for the treatment of psoriasis: a review of phase III trails","volume":"6","author":"Farahnik","year":"2016","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejmech.2021.114065_bib7","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1021\/jm401901d","article-title":"Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-\u03b3 (ROR\u03b3 or RORc)","volume":"57","author":"Fauber","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114065_bib8","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1021\/acs.jmedchem.8b00588","article-title":"Combating autoimmune diseases with retinoic acid Receptor Related orphan receptor-\u03b3 (ROR\u03b3 or RORc) inhibitors: hits and misses","volume":"61","author":"Pandya","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114065_bib9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2021.114065_bib10","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.aaa4282","article-title":"Impairment of immunity to candida and mycobacterium in humans with bi-allelic RORC mutations","volume":"349","author":"Okada","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.114065_bib11","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1021\/acs.jmedchem.8b00783","article-title":"Potent and orally bioavailable inverse agonists of ROR\u03b3t resulting from structure-based design","volume":"61","author":"Narjes","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114065_bib12","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1021\/acs.jmedchem.8b00061","volume":"61","author":"Kono","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114065_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1021\/acsmedchemlett.5b00253","article-title":"SAR exploration guided by LE and Fsp3: discovery of a selective and orally efficacious ROR\u03b3 inhibitor","volume":"7","author":"Hirata","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114065_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejmech.2019.01.082","article-title":"Discovery of N-indanyl benzamides as potent RORgt inverse agonists","volume":"167","author":"Tian","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114065_bib15","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.1021\/acs.jmedchem.8b00529","article-title":"Optimizing a weakly binding fragment into a potent ROR\u03b3t inverse agonist with efficacy in an in\u00a0vivo inflammation model","volume":"61","author":"Carcache","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114065_bib16","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1021\/acs.jmedchem.5b00597","volume":"58","author":"Fauber","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114065_bib17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543776.2016.1153066","article-title":"Retinoid-related orphan receptor gamma t (ROR\u03b3t) inhibitors from Vitae Pharmaceuticals (WO2015116904) and structure proposal for their Phase I candidate VTP-43742","volume":"26","author":"Gege","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2021.114065_bib18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/acsmedchemlett.5b00122","article-title":"Discovery of biaryl amides as potent, orally bioavailable, and CNS penetrant ROR\u03b3t inhibitors","volume":"6","author":"Wang","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114065_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/mol.109.060905","article-title":"The benzenesulfonamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-(trifluoromethyl)ethyl]phenyl] benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-\u03b1\/\u03b3 inverse agonist","volume":"77","author":"Kumar","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114065_bib20","series-title":"Drug Design and Delivery Symposium, October 26, 2017","article-title":"The discovery of AZD0284, an inverse agonist of the nuclear receptor ROR\u03b3","author":"Narjes","year":"2017"},{"key":"10.1016\/j.ejmech.2021.114065_bib21","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/bjd.16131","article-title":"A\u00a0phase I randomised controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test","volume":"178","author":"Kang","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejmech.2021.114065_bib22","series-title":"Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis","year":"2018"},{"key":"10.1016\/j.ejmech.2021.114065_bib23","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/13543776.2019.1655541","article-title":"Retinoic acid receptor-related orphan receptor gamma-t (ROR\u03b3t) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present)","volume":"29","author":"Sun","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"issue":"8","key":"10.1016\/j.ejmech.2021.114065_bib24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.bmcl.2018.03.041","article-title":"Sulfoximines as potent ROR\u03b3 inverse agonists","volume":"28","author":"Ouvry","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114065_bib25","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1210\/me.2009-0507","article-title":"Structural basis for hydroxycholesterols as natural ligands of orphan nuclear receptor RORgamma","volume":"24","author":"Jin","year":"2010","journal-title":"Mol. Endocrinol."},{"issue":"3","key":"10.1016\/j.ejmech.2021.114065_bib26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/acsmedchemlett.9b00010","article-title":"Structure-based discovery of phenyl (3-phenylpyrrolidin-3-yl)sulfones as selective, orally active ROR\u03b3t inverse agonists","volume":"10","author":"Duan","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114065_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/17460441003605098","article-title":"Lipophilicity in drug discovery","volume":"5","author":"Waring","year":"2010","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.114065_bib28","series-title":"Sulfonamide Compounds and Their Use in the Modulation Retinoid-Related Orphan Receptor","author":"Birault","year":"2015"},{"key":"10.1016\/j.ejmech.2021.114065_bib29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on Decision-making in Medicinal Chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.114065_bib30","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2021.114065_bib31","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2021.114065_bib32","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","article-title":"Physiochemical drug properties associated with in\u00a0vivo toxicological outcomes","volume":"18","author":"Hughes","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.ejmech.2021.114065_bib33","first-page":"45","article-title":"The potential pharmacological and toxicological impact of P450 screening","volume":"4","author":"Riley","year":"2001","journal-title":"Curr. Opin. Drug Discov. Dev"},{"key":"10.1016\/j.ejmech.2021.114065_bib34","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Van der Fits","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ejmech.2021.114065_bib35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/jid.2012.318","article-title":"An alternative pathway of imiquimod-Induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling","volume":"133","author":"Malki","year":"2013","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2021.114065_bib36","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cmdc.201700278","article-title":"Structural states of ROR\u03b3t: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds","volume":"12","author":"Kallen","year":"2017","journal-title":"ChemMedChem"},{"issue":"15","key":"10.1016\/j.ejmech.2021.114065_bib37","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.1021\/acs.jmedchem.0c02178","article-title":"Agonist lock touched and untouched retinoic acid receptor-related orphan receptor-\u03b3t (ROR\u03b3t) inverse agonists: classification based on the molecular mechanisms of action","volume":"64","author":"Sun","year":"2021","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:36:01Z","timestamp":1759329361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421009144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":37,"alternative-id":["S0223523421009144"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114065","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 2H-chromone-4-one based sulfonamide derivatives as potent retinoic acid receptor-related orphan receptor \u03b3t inverse agonists","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114065"}}